Changing paradigm of prophylaxis with longer acting factor concentrates.
about
Gene therapy for haemophiliaFusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Management of hemophilia in Korea: the past, present, and future.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Current and future prospects for hemophilia gene therapy.Advances in the treatment of bleeding disorders.Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment.Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany.Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.Preference-based valuation of treatment attributes in haemophilia A using web survey.Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.GlycoPEGylated recombinant factor IX for hemophilia B in contextUpdates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
P2860
Q24187977-48866A0B-1889-444C-8520-71449AABF0CCQ26801319-C10DEE73-2548-4859-AC73-D2EFF75DD644Q30249256-C11FC6C4-BD80-474D-B3D0-84DAB242B21BQ34302456-21F72D63-A452-40CA-B22D-8C52BFF6E567Q34503723-0ADE4E4F-7D23-4777-BC68-A6704B96AEBAQ35565320-505D9225-4C75-430E-8CCD-2D43195E12C9Q38827606-E6A09A27-1309-4B2D-A3E7-C94224E29B4BQ38945123-F2DC9BBC-AF52-4B9E-9686-1B1A0D051525Q39252827-70B2FEB1-28D7-4680-A9CC-3423A77A9896Q40007308-1493917E-4906-4AC1-A7CD-A1A31D085BFEQ40268971-A576411C-8E9D-4D14-BBB9-DA1F212E5E32Q41591597-8B5F4B30-2F34-4F5C-9D1E-02B19F57182EQ44576554-C8880BD9-2FD7-4813-AF3C-B08B0BC54A5BQ45232152-5ABD4FD0-A3A1-4039-9B71-7391AFCD538EQ45866421-42E6A43B-E291-4593-B2CE-4DEC24CA0C35Q45871318-4DB1442D-4907-42E5-99DD-050C61AD6627Q45885955-0F9043C7-FF39-42A5-8922-21EE2B167A67Q47697767-026B1561-B863-44E5-A899-F1DB73DA6B89Q57158345-76AC60C6-1273-4313-AC8C-9337F626F707Q58583115-B36B78E7-BD04-41AD-ACEB-5F1361A0D4F3
P2860
Changing paradigm of prophylaxis with longer acting factor concentrates.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Changing paradigm of prophylaxis with longer acting factor concentrates.
@en
type
label
Changing paradigm of prophylaxis with longer acting factor concentrates.
@en
prefLabel
Changing paradigm of prophylaxis with longer acting factor concentrates.
@en
P2860
P356
P1433
P1476
Changing paradigm of prophylaxis with longer acting factor concentrates.
@en
P2093
P2860
P304
P356
10.1111/HAE.12405
P478
20 Suppl 4
P577
2014-05-01T00:00:00Z